Dimai Hans Peter, Pietschmann Peter, Resch Heinrich, Preisinger Elisabeth, Fahrleitner-Pammer Astrid, Dobnig Harald, Klaushofer Klaus
Klinische Abteilung für Endokrinologie und Nuklearmedizin, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria.
Wien Med Wochenschr Suppl. 2009(122):1-34. doi: 10.1007/s10354-009-0656-x.
Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence that a combination of two or more of these drugs could improve anti-fracture potency. However, treatment with PTH should be followed by the treatment with an anticatabolic drug such as bisphosphonates. Calcium and vitamin D constitute an important adjunct to any osteoporosis treatment.
骨质疏松症是一种全身性骨骼疾病，其特征为骨量减少和骨微结构破坏，导致骨骼脆性增加，进而使骨折风险升高。因此，治疗措施旨在降低个体骨折风险。在奥地利，目前已注册用于治疗绝经后骨质疏松症的药物如下，所有这些药物均已被证实可降低骨折风险：阿仑膦酸盐、利塞膦酸盐、依替膦酸盐、伊班膦酸盐、雷洛昔芬、特立帕肽（1-34 甲状旁腺激素）、1-84 甲状旁腺激素、雷奈酸锶和鲑降钙素。氟化物仍可获取，但它们在日常实践中的作用已变得微不足道。目前，尚无证据表明两种或更多种此类药物联合使用可提高抗骨折效力。然而，使用甲状旁腺激素治疗后应接着使用抗分解代谢药物，如双膦酸盐。钙和维生素 D 是任何骨质疏松症治疗的重要辅助药物。
